Creating sustainability and longevity for biosimilars
At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.
RICK LOZANO, VICE PRESIDENT, BIOSIMILARS, AMERISOURCEBERGEN
"Recent patent litigation decisions signal that supporters of the biosimilar channel need to work even harder to communicate the value and opportunity for these products and create confidence among payers, providers and patients."
We advance access with integrated commercialization services for all biosimilars
AmerisourceBergen has access to 100% of launched biosimilars in the U.S.
For a complete list of approved biosimilars, refer to FDA biosimilar product information. Commercial launches can take 10-12 months from FDA approval.
Our relationships span:
health systems
95%
of u.s. hospitals
oncology
60%
of U.S. community oncology market
nephrology
90%
of U.S. renal market
rheumatology
2,100
provider sites
opHthamology
4,200
provider sites
Resources & Education
Read the FDA's guidance on biosimilars and get answers to patients' frequently asked questions.
Connect With an Expert
Find out more about how AmerisourceBergen can support your product or practice as the biosimilars market in the U.S. expands.
